1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E3FDC99EE44CFF3785257CA7006ABB29
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-disease-state-awareness-programs-orphan-drugs?OpenDocument
18
19OpenDocument
203.81.28.94
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Planning and Coordinating Launch Communication Activities

Disease State Awareness Programs for Orphan Drugs

DB Image

ID: 5301


Features:

10 Info Graphics

3 Narratives


Pages/Slides: 15


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
STUDY OVERVIEW

Pharmaceutical companies use disease state awareness programs to raise awareness among consumers and healthcare practitioners about a disease or health condition, especially those that are not widely understood or recognized. While these awareness programs do not mention potential therapies, typically companies do awareness programs around conditions that they have therapies for, or are developing therapies for.

The principal goal of disease state awareness programs for HCPs is to help them better diagnose diseases through a complete understanding of the clinical and physical traits of the disease. Disease awareness programs are considered vital for orphan products given that these therapies are for patients who are often difficult to diagnose.


Best Practices, LLC conducted this short study to inform biopharmaceutical organizations about current approaches to disease awareness programs for orphan products. Using three orphan products as examples, the study explores program goals, content, timing and execution for each of the three products.



KEY TOPICS

  • Business Issue/Study Questions
  • Metreleptin Case Study
  • Soliris Case Study
  • Kalydeco Case Study
  • Qualitative Insights

KEY STUDY QUESTIONS
  • What were the goals for the disease awareness program?
  • What was the content of the disease awareness program?
  • When was the disease awareness program launched?
  • Who executed the disease awareness program?
SAMPLE KEY FINDING

Sales is not Involved in disease education until post-launch, if at all. There is a general consensus that sales – even specialty sales – is not involved in disease state education for orphan products. This is particularly true pre-approval and pre-launch. Organizations rely on their medical or scientific field force to execute disease awareness for HCPs. It appears some organizations use specialty sales for general education post-launch but they do not handle discussions around science, treatments or off-label uses.

METHODOLOGY

Best Practices, LLC reviewed three orphan drug Disease Awareness programs – two approved products and one that is under review. Researchers performed secondary research and primary research that included interviews with two vendors that have done orphan product Disease Awareness and two medical affairs leaders from organizations that have orphan products.

Industries Profiled:
Pharmaceutical


Companies Profiled:
AstraZeneca; Alexion Pharmaceuticals; Bristol-Myers Squibb; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.